Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 2
2020 5
2021 10
2022 8
2023 21
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean arsic (321 results)?
Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer.
Devos G, Devlies W, De Meerleer G, Baldewijns M, Gevaert T, Moris L, Milonas D, Van Poppel H, Berghen C, Everaerts W, Claessens F, Joniau S. Devos G, et al. Nat Rev Urol. 2021 Dec;18(12):739-762. doi: 10.1038/s41585-021-00514-9. Epub 2021 Sep 15. Nat Rev Urol. 2021. PMID: 34526701 Review.
The addition of ARSIs to androgen deprivation therapy has demonstrated substantial survival benefits in the metastatic castration-resistant, non-metastatic castration-resistant and metastatic hormone-sensitive settings. Intuitively, a similar survival effect can be expecte …
The addition of ARSIs to androgen deprivation therapy has demonstrated substantial survival benefits in the metastatic castration-res …
Treating Prostate Cancer by Antibody-Drug Conjugates.
Rosellini M, Santoni M, Mollica V, Rizzo A, Cimadamore A, Scarpelli M, Storti N, Battelli N, Montironi R, Massari F. Rosellini M, et al. Int J Mol Sci. 2021 Feb 4;22(4):1551. doi: 10.3390/ijms22041551. Int J Mol Sci. 2021. PMID: 33557050 Free PMC article. Review.
At the same time, several trials have shown the survival benefits related to the administration of novel ARSIs among patients with non-castration-resistant metastatic disease along with nonmetastatic castration-resistant cancer too. ...
At the same time, several trials have shown the survival benefits related to the administration of novel ARSIs among patients with no …
Current therapy and drug resistance in metastatic castration-resistant prostate cancer.
Cai M, Song XL, Li XA, Chen M, Guo J, Yang DH, Chen Z, Zhao SC. Cai M, et al. Drug Resist Updat. 2023 May;68:100962. doi: 10.1016/j.drup.2023.100962. Epub 2023 Apr 14. Drug Resist Updat. 2023. PMID: 37068396 Free article. Review.
In this review, we aim to review new insight of the treatment of mCRPC and elucidate mechanisms governing resistance to new drugs: taxanes, androgen receptor signaling inhibitors (ARSIs) and poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi). ...
In this review, we aim to review new insight of the treatment of mCRPC and elucidate mechanisms governing resistance to new drugs: taxanes, …
Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.
Yanagisawa T, Rajwa P, Thibault C, Gandaglia G, Mori K, Kawada T, Fukuokaya W, Shim SR, Mostafaei H, Motlagh RS, Quhal F, Laukhtina E, Pallauf M, Pradere B, Kimura T, Egawa S, Shariat SF. Yanagisawa T, et al. Eur Urol. 2022 Dec;82(6):584-598. doi: 10.1016/j.eururo.2022.08.002. Epub 2022 Aug 19. Eur Urol. 2022. PMID: 35995644 Free article. Review.
CONTEXT: Recent randomized controlled trials (RCTs) examined the role of adding androgen receptor signaling inhibitors (ARSIs), including abiraterone acetate (ABI), apalutamide, darolutamide (DAR), and enzalutamide (ENZ), to docetaxel (DOC) and androgen deprivation therapy …
CONTEXT: Recent randomized controlled trials (RCTs) examined the role of adding androgen receptor signaling inhibitors (ARSIs), inclu …
Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review.
Hatano K, Nonomura N. Hatano K, et al. World J Mens Health. 2023 Oct;41(4):769-784. doi: 10.5534/wjmh.220200. Epub 2023 Jan 27. World J Mens Health. 2023. PMID: 36792090 Free PMC article. Review.
Bone-modifying agents have become part of the overall treatment strategy for mCRPC, in which denosumab and zoledronic acid reduce skeletal-related events. Recently, androgen receptor-signaling inhibitors (ARSIs) and docetaxel have been used upfront against metastatic castr …
Bone-modifying agents have become part of the overall treatment strategy for mCRPC, in which denosumab and zoledronic acid reduce skeletal-r …
Cross-resistance and drug sequence in prostate cancer.
Buck SAJ, Koolen SLW, Mathijssen RHJ, de Wit R, van Soest RJ. Buck SAJ, et al. Drug Resist Updat. 2021 May;56:100761. doi: 10.1016/j.drup.2021.100761. Epub 2021 Mar 18. Drug Resist Updat. 2021. PMID: 33799049 Free article. Review.
With the increasing use of ARSIs in earlier disease stages, cross-resistance between treatments has emerged, which is a dominant impediment in current clinical practice. To overcome cross-resistance in the treatment of prostate cancer, it is of paramount importance to deci …
With the increasing use of ARSIs in earlier disease stages, cross-resistance between treatments has emerged, which is a dominant impe …
Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance.
Jamroze A, Chatta G, Tang DG. Jamroze A, et al. Cancer Lett. 2021 Oct 10;518:1-9. doi: 10.1016/j.canlet.2021.06.006. Epub 2021 Jun 10. Cancer Lett. 2021. PMID: 34118355 Free PMC article. Review.
Unfortunately, the clinical efficacy of ARSIs is short-lived and the majority of treated patients develop castration-resistant PCa (CRPC). ...While AR(+) PCa cells/clones exhibit exquisite sensitivities to ARSIs, AR(-/lo) PCa cells/clones, which are greatly enriched …
Unfortunately, the clinical efficacy of ARSIs is short-lived and the majority of treated patients develop castration-resistant PCa (C …
Is It Time to Anticipate the Use of PARP Inhibition in Prostate Cancer Patients?
Sciarra A, Santarelli V, Santodirocco L, Frisenda M, Salciccia S, Casale P, Forte F, Mariotti G, Moriconi M, Cattarino S, Sciarra B, Bevilacqua G, Gentilucci A. Sciarra A, et al. Curr Oncol. 2023 Aug 30;30(9):8054-8067. doi: 10.3390/curroncol30090584. Curr Oncol. 2023. PMID: 37754499 Free PMC article. Review.
The new message emerging is that the combination of PARPis with ARSIs may work independently of DDR mutational status. As a matter of fact, most of the recent trials analyzing the combination of PARPis with abiraterone or enzalutamide as a first-line therapy enrolled mCRPC …
The new message emerging is that the combination of PARPis with ARSIs may work independently of DDR mutational status. As a matter of …
Targeting hyaluronan-mediated motility receptor (HMMR) enhances response to androgen receptor signalling inhibitors in prostate cancer.
Hinneh JA, Gillis JL, Mah CY, Irani S, Shrestha RK, Ryan NK, Atsushi E, Nassar ZD, Lynn DJ, Selth LA, Kato M, Centenera MM, Butler LM. Hinneh JA, et al. Br J Cancer. 2023 Oct;129(8):1350-1361. doi: 10.1038/s41416-023-02406-8. Epub 2023 Sep 6. Br J Cancer. 2023. PMID: 37673961 Free PMC article.
BACKGROUND: Resistance to androgen receptor signalling inhibitors (ARSIs) represents a major clinical challenge in prostate cancer. ...CONCLUSION: Co-targeting HMMR and AR represents an effective strategy for improving response to ARSIs....
BACKGROUND: Resistance to androgen receptor signalling inhibitors (ARSIs) represents a major clinical challenge in prostate cancer. . …
A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer.
Zhao SG, Sperger JM, Schehr JL, McKay RR, Emamekhoo H, Singh A, Schultz ZD, Bade RM, Stahlfeld CN, Gilsdorf CS, Hernandez CI, Wolfe SK, Mayberry RD, Krause HM, Bootsma M, Helzer KT, Rydzewski N, Bakhtiar H, Shi Y, Blitzer G, Kyriakopoulos CE, Kosoff D, Wei XX, Floberg J, Sethakorn N, Sharifi M, Harari PM, Huang W, Beltran H, Choueiri TK, Scher HI, Rathkopf DE, Halabi S, Armstrong AJ, Beebe DJ, Yu M, Sundling KE, Taplin ME, Lang JM. Zhao SG, et al. J Clin Invest. 2022 Nov 1;132(21):e161858. doi: 10.1172/JCI161858. J Clin Invest. 2022. PMID: 36317634 Free PMC article.
We next profiled 116 longitudinal samples from a prospectively collected institutional cohort of 17 patients with metastatic prostate cancer (7 NEPC, 10 adenocarcinoma) as well as 265 samples from 139 patients enrolled in 3 adenocarcinoma phase II trials of androgen receptor sign …
We next profiled 116 longitudinal samples from a prospectively collected institutional cohort of 17 patients with metastatic prostate cancer …
51 results